Anixa Biosciences Dirección
Dirección controles de criterios 2/4
El CEO de Anixa Biosciences' es Amit Kumar , nombrado en Jul 2017, tiene una permanencia de 6.75 años. compensación anual total es $3.64M, compuesta por 19.8% salario y 80.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.54% de las acciones de la empresa, por valor de $1.51M. La antigüedad media del equipo directivo y de la junta directiva es de 7.1 años y 5.5 años, respectivamente.
Información clave
Amit Kumar
Chief Executive Officer (CEO)
US$3.6m
Compensación total
| Porcentaje del salario del CEO | 19.8% |
| Permanencia del CEO | 6.8yrs |
| Participación del CEO | 1.5% |
| Permanencia media de la dirección | 7.1yrs |
| Promedio de permanencia en la Junta Directiva | 5.5yrs |
Actualizaciones recientes de la dirección
Recent updates
We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn
Jan 19
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
Oct 06Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?
Apr 27Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?
Jan 13We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Sep 26Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial
Aug 15Anixa to get additional US patent linked to breast cancer vaccine technology
Jul 21Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jun 13Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
May 11We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow
Feb 24Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth
Oct 28Our First Look At Anixa Biosciences
Sep 23Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation
Jun 12OntoChem assigns Anixa covid-19 drug discovery project to MolGenie
May 07Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans
Jan 13
Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact
Dec 01Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jan 31 2024 | n/a | n/a | -US$11m |
| Oct 31 2023 | US$4m | US$720k | -US$10m |
| Jul 31 2023 | n/a | n/a | -US$11m |
| Apr 30 2023 | n/a | n/a | -US$11m |
| Jan 31 2023 | n/a | n/a | -US$12m |
| Oct 31 2022 | US$2m | US$631k | -US$14m |
| Jul 31 2022 | n/a | n/a | -US$14m |
| Apr 30 2022 | n/a | n/a | -US$16m |
| Jan 31 2022 | n/a | n/a | -US$15m |
| Oct 31 2021 | US$11m | US$573k | -US$13m |
| Jul 31 2021 | n/a | n/a | -US$11m |
| Apr 30 2021 | n/a | n/a | -US$9m |
| Jan 31 2021 | n/a | n/a | -US$10m |
| Oct 31 2020 | US$2m | US$522k | -US$10m |
| Jul 31 2020 | n/a | n/a | -US$10m |
| Apr 30 2020 | n/a | n/a | -US$9m |
| Jan 31 2020 | n/a | n/a | -US$9m |
| Oct 31 2019 | US$665k | US$476k | -US$12m |
| Jul 31 2019 | n/a | n/a | -US$15m |
| Apr 30 2019 | n/a | n/a | -US$18m |
| Jan 31 2019 | n/a | n/a | -US$17m |
| Oct 31 2018 | US$12m | US$425k | -US$14m |
| Jul 31 2018 | n/a | n/a | -US$10m |
| Apr 30 2018 | n/a | n/a | -US$7m |
| Jan 31 2018 | n/a | n/a | -US$5m |
| Oct 31 2017 | US$454k | US$300k | -US$7m |
Compensación vs. Mercado: La compensación total de Amit($USD3.64M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Amit ha aumentado mientras la empresa no es rentable.
CEO
Amit Kumar (59 yo)
6.8yrs
Permanencia
US$3,639,651
Compensación
Dr. Amit Kumar, Ph.D. was a Director at Ascent Solar Technologies, Inc. since June 2007 until September 16, 2022 and had been its Independent Chairman of the Board since January 2011 until September 16, 20...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, Chairman & Co-Chair of CBAB | 6.8yrs | US$3.64m | 1.54% $ 1.6m | |
| President | 7.4yrs | US$1.97m | 0.087% $ 89.7k | |
| Senior Vice President of Engineering | 11.6yrs | US$275.00k | sin datos | |
| Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | 2.6yrs | sin datos | sin datos |
7.1yrs
Permanencia media
63yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ANIX es experimentado (7.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, Chairman & Co-Chair of CBAB | 11.4yrs | US$3.64m | 1.54% $ 1.6m | |
| Chief Development Officer & Chair Breast Cancer Clinical Advisory Board | 1.2yrs | sin datos | sin datos | |
| Lead Independent Director | 6.8yrs | US$267.60k | 2.63% $ 2.7m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.5yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 4.5yrs | sin datos | sin datos | |
| Member of Breast Cancer Clinical Advisory Board | 1.2yrs | sin datos | sin datos | |
| Member of SAB & Breast Cancer Clinical Advisory Board | 5.6yrs | US$169.35k | 0.34% $ 355.3k | |
| Member of Scientific Advisory Board | 5.5yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.5yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.5yrs | sin datos | sin datos | |
| Independent Director | 4.5yrs | US$169.35k | 0.14% $ 147.5k |
5.5yrs
Permanencia media
68.5yo
Promedio de edad
Junta con experiencia: La junta directiva de ANIX se considera experimentada (5.5 años de antigüedad promedio).